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Imatinib mesylate is a tyrosine kinase inhibitor of c-KIT and PDGFRA. Imatinib mesylate is an eﬀective drug that can be used as
a ﬁrst-choice agent for treatment of GISTs. Prior to treatment, molecular diagnosis of c-KIT or PDGFRA is necessary; however,
in some types of GISTs, it is impossible to obtain a suﬃcient amount of specimen for diagnosis. An inoperable or marginally
resectable GIST in a 79-year-old female was diﬃcult to be diagnosed at a molecular pathological level, and hence, exploratory
treatment was initiated using imatinib combined with 18FDG-PET evaluation at 1-month intervals. PET imaging indicated a
positive response, and so we continued imatinib treatment in an NAC setting for 4 months. As a result, curative resection of
the entire tumor was successfully performed with organ preservation and minimally invasive surgery. 18FDG-PET evaluation at
1-month intervals is beneﬁcial for GISTs that are diﬃcult to be diagnosed histopathologically.
1.Introduction
Gastrointestinal stromal tumors (GISTs) are a type of
submucosal tumor (SMT) with a malignant phenotype,
derived from interstitial cells of Cajal [1]. It is estimated
that the incidence of GISTs is approximately 10 to 20 per
million people every year [1]. Oncogenic activation of c-KIT
or platelet-derived growth factor receptor α (PDGFRA) is
responsible for molecular carcinogenesis of GIST [1]. Ima-
tinib mesylate (Ima) is eﬀective for inoperable or metastatic
GISTs with permissive toxicities [2–4]. Application of Ima
in adjuvant chemotherapy and neoadjuvant chemotherapy
(NAC) setting is still under clinical investigations.
Molecular histpathological analysis is necessary for the
diagnosis of GISTs. However, SMTs such as GISTs are
often diﬃcult to sample. In this paper, we succeeded in
using exploratory treatment combined with 18Fluorodeoxy-
glucose-positron emission computed tomography (18FDG-
PET) as an alternative method for diagnosing GISTs.
2. Case Presentation
A 79-year-old Japanese female consulted Akita University
Hospital on December 2009 with a history of progressive
diﬃculty with defecation. Abdominal ultrasound (US),
abdominal computed tomography (CT) images, and mag-
netic resonance images (MRIs) revealed a tumor with a
maximum diameter of 5.5cm, occupying the whole cavity of
pelvis minor, within the posterior wall of the lower rectum
(Figure 1). The T1-weighted image of the tumor showed2 Case Reports in Oncological Medicine
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Figure 1: MRI imaging of tumor (T1-weighted (a), T2-weighted
(b), and diﬀusion-weighted (c) images).
a low-signal intensity that was identical to that of smooth
muscle. Both the T2-weighted and the diﬀusion-weighted
images showed heterogeneous, intermediate-to-high signal
intensities in the tumor that were enhanced with intravenous
gadolinium chelate. Colonoscopy revealed no mucosal ﬁnd-
ings except a submucosal mass (Figure 2). Endoscopic US
examinations revealed a low-echoic and irregular pattern
in the tumor. 18FDG-PET showed marked increased uptake
in the rectal tumor (Figure 3(a)). The maximal standard
uptake value (SUV-max) was 17.4. Results of laboratory
workup were almost within normal limits. Judging from
this extent, the tumor was not respectable at the expense of
rectal amputation, but the risk of iatrogenic tumor rapture
and/or injury to the pudendal plexus seemed to be very high.
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Figure 2: Endoscopic (a, b) and EUS (c) ﬁndings.
From the risk of bleeding or seeding into the pelvic cavity,
biopsy was avoided. Images of the tumor, especially the T2-
weighted image, highly suggested the diagnosis of GIST [5].
In this context, initiation of Ima treatment in an NAC setting
was worthwhile based on the condition that evaluation of
the antitumor eﬀect should be performed after 1month of
treatment. Informed consent was obtained from the patient
stating the advantages and disadvantages of the treatment,
that is, NAC with Ima. After 5 weeks of administration at a
standard dose or less (200–400mg/day), the antitumor eﬀect
was evaluated by 18FDG-PET or CT. SUV-max decreased
to that of the background level, and the sum of the largestCase Reports in Oncological Medicine 3
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Figure 3: 18FDG-PET/CT imaging prior to Ima treatment (a, b) and 1 month after treatment (c, d).
diameter of the tumor to 71% of baseline (Figure 3(c)).
The main reasons for dose reduction were anorexia. This
tumor was diagnosed as an Ima-sensitive GIST. NAC with
Ima was continued for 4 months. Due to the gradually
lower compliance of Ima, it was considered that the maximal
shrinkage was obtained at this point, and therefore, the
patient underwent surgery. Under abdominosacral approach
with laparoscopic assistance, complete tumor resection was
attained only with a partial resection of the rectal wall.
Histopathologicalanalysisofthesurgicalspecimenidentiﬁed
a gray-white elastic soft tumor of 5cm diameter. No viable
cells were observed in two-third portion of the tumor, which
presented as liquefactive necrosis or hyaline degeneration.
The other part mainly contained spindle-type cells that
showed positive staining with CD117 (c-KIT) and CD34,
(Figures 4(a), 4(b),a n d4(c)). Almost no mitotic ﬁgures and
very low Ki-67 positivity (0.1%) was observed (Figure 4(d)).
Thus, it was concluded that an R0 resection had been
performed.Molecularanalysisidentiﬁedadeletionmutation
of codon 557/558 in exon 11 of the c-KIT gene (557/558 del).
Adjuvant chemotherapy with Ima was not performed due to
the patient’s refusal. After 6 months of followup, there was
no evidence of local or distant recurrence.
3. Discussion
Inoperable, metastatic, or marginally resectable GISTs are
good targets for Ima treatment. Molecular diagnosis con-
ﬁrming c-KIT- or PDGFRA-positive GISTs is a precondition
for Ima treatment. However, it is often diﬃcult to obtain
as u ﬃcient amount of specimens from SMT-like GISTs.
Even with endoscopic ultrasound-guided trucut biopsy, no
adequate specimen for diagnosis can be obtained in as many
as 37% of gastric SMTs [6]. In 2 out of 52 trucut biopsy
procedures, severe septic complications were reported [6].
On the other hand, 18FDG-PET is rather harmless and
can evaluate the response accurately in 85% of patients at
1 month, whereas CT can evaluate the response in 44%
of patients at the same time period [7]. 18FDG is simply
reﬂected by elevated glycolysis of cancer cells. 125Iodine-
and 111Indium-labeled anti-c-KIT antibodies are still under
investigation [8]. Evaluation by a second 18FDG-PET at 1
month is a good surrogate marker of therapeutic response.
Thus, exploratory treatment with Ima is permissible, and
the issue concerning irradiation was negligible. The average
eﬀective dose of a PET scan is 14.1mSv, that is twice higher
than that of a chest CT [9]. However, the maximum annual
additional risk for the incidence of cancer is estimated to
be 0.019% [9]. Four-month NAC is appropriate against the
recent result concerning a phase 2 NAC study of GIST, where
Ima (600mg/day) was continued for 8 to 12 weeks prior to
surgery with minimal complications [10]. NAC was proven
to be beneﬁcial against a large tumor (>5cm)andtumors
thatwerepotentiallymorbidonresectionfromtheviewpoint
of organ preservation and minimally invasive surgery [11].
The prognosis of GISTs bearing the deletion mutation in
exon 11 of the c-KIT gene is very poor [12]. However, the
therapeutic beneﬁt with Ima was exceptional for a 557/558
del, and it has been shown that progression-free survival is
p r o l o n g e do v e r4y e a r sw i t hI m a[ 13].4 Case Reports in Oncological Medicine
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Figure 4: Histopathological analysis of the tumor: (a) HE, (b) CD117, (c) CD34, and (d) Ki-67.
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